Cabazitaxel in metastatic castration-resistant prostate cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 9, 2012, Pages 1129-1136

  Yap, Timothy A ^a   Pezaro, Carmel J ^a   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

abiraterone; cabazitaxel; castration resistant prostate cancer; docetaxel; Jevtana ; MDV3100

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; BAVITUXIMAB; CABAZITAXEL; CARBOPLATIN; CUSTIRSEN; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; OCTREOTIDE; PLACEBO; PREDNISOLONE; PREDNISONE; RADIUM CHLORIDE RA 223; SATRAPLATIN; TASQUINIMOD;

ADD ON THERAPY; ADVANCED CANCER; AREA UNDER THE CURVE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG RESEARCH; DRUG RESPONSE; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; VOMITING;

ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DISEASE RESISTANCE; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; ORCHIECTOMY; POSTOPERATIVE COMPLICATIONS; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84867967078     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.88     Document Type: Review

References (29)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA. Cancer J. Clin. 60(5), 277-300 (2010).
2. Pienta KJ, Bradley D. Mechanisms underlying the development of androgenindependent prostate cancer. Clin. Cancer Res. 12(6), 1665-1671 (2006).
3. Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat. Rev. Clin. Oncol. 8(10), 597-610 (2011).
4. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346(8970), 265-269 (1995).
5. Figg WD, Sartor O, Cooper MR et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am. J. Med. 98(4), 412-414 (1995).
6. Nishimura K, Nonomura N, Yasunaga Y et al. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89(12), 2570-2576 (2000). (Pubitemid 32011601)
7. Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a Phase III trial (CALGB 9583). J. Clin. Oncol. 22(6), 1025-1033 (2004). (Pubitemid 41095034)
8. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004). (Pubitemid 39315318)
9. Tannock IF, de Wit R, Berry WR et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004). (Pubitemid 39315317)
10. Gan L, Chen S, Wang Y et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 69(21), 8386-8394 (2009).
11. Scher HI, Heller G, Molina A et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled Phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J. Clin. Oncol. 29, Abstract LBA4517 (2011).
12. de Bono JS, Logothetis CJ, Molina A et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011).
13. Scher HI, Fizazi K, Saad F et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the Phase III AFFIRM study. J. Clin. Oncol. 30, Abstract LBA1 (2012).
14. Parker C, Heinrich D, O'Sullivan JM et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a Phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J. Clin. Oncol. 30, Abstract 8 (2012).
15. Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF; TAX 327 Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann. Oncol. 19(10), 1749-1753 (2008).
16. Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, Phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J. Clin. Oncol. 27(32), 5431-5438 (2009).
17. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat. Rev. Clin. Oncol. 7(1), 22-36 (2010).
18. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat. Rev. Drug Discov. 9(9), 677-678 (2010).
19. Mita AC, Denis LJ, Rowinsky EK et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 15(2), 723-730 (2009).
20. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 268(20), 14991-14997 (1993). (Pubitemid 23206648)
21. Bissery M-C, Bouchard H, Riou JF, Vrignaud P, Combeau C, Bourzat JD. Preclinical evaluation of TXD258, a new taxoid. Proc. Am. Assoc. Cancer Res. 41, Abstract 1364 (2000).
22. Pivot X, Koralewski P, Hidalgo JL et al. A multicenter Phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol. 19(9), 1547-1552 (2008).
23. de Bono JS, Oudard S, Ozguroglu M et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147-1154 (2010).
24. Bahl A, Masson S, Malik Z et al. Cabazitaxel for metastatic castrationresistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279). J. Clin. Oncol. 30, Abstract 44 (2012).
25. Di Lorenzo G, Buonerba C, Faiella A et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 107(2), 234-239 (2011).
26. Ryan CJ, Smith MR, de Bono JS et al. on behalf of the COU-AA-302 Investigators. Interim analysis (IA) results of COUAA- 302, a randomized, Phase III study of abiraterone acetate (AA) in chemotherapynaive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Clin. Oncol. 30, Abstract LBA4518 (2012).
27. Sartor AO, Oudard S, Ozguroglu M et al. Prognostic factors for survival in the Phase III TROPIC trial. J. Clin. Oncol. 30(Suppl. 5), Abstract 102 (2012).
28. Attard G, Greystoke A, Kaye S, De Bono J. Update on tubulin-binding agents. Pathol. Biol. 54(2), 72-84 (2006).
29. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14(19), 6302-6309 (2008).